anti-CD19 CAR T-cell therapy (Biocure/Pharos Vaccine)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Biocure/Pharos Vaccine)
Drug Alias Nameanti-CD19 CAR T-cell therapy (Biocure)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaGermanySouth Korea +[4] 
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesPharos Vaccine Inc
China Registration ClassN/A

Develop Information

Active CompaniesPharos Vaccine IncBiocure Technology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A